EcoDrugPlus

Proteasome 20s Subunit Alpha 5

Ensembl ID : ENSAOCG00000013219
Gene Symbol: PSMA5
3 Cross references
212 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSAOCG00000020197
Gene Symbol: PSMB1
3 Cross references
219 Possible Orthologues:

Proteasome 20s Subunit Beta 11b

Ensembl ID : ENSAOCG00000022715
Gene Symbol: PSMB11B
1 Cross references
161 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSAOCG00000019430
Gene Symbol: PSMB2
1 Cross references
204 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSAOCG00000019661
Gene Symbol: PSMB3
3 Cross references
261 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSAOCG00000001479
Gene Symbol: PSMB4
3 Cross references
215 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSAOCG00000015323
Gene Symbol: PSMB6
3 Cross references
228 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSAOCG00000004464
Gene Symbol: PSMB8
3 Cross references
216 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSAOCG00000005561
Gene Symbol: PSMC1
3 Cross references
318 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSAOCG00000018060
Gene Symbol: PSMC2
3 Cross references
233 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSAOCG00000020227
Gene Symbol: PSMC3
3 Cross references
227 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSAOCG00000006477
Gene Symbol: PSMC4
3 Cross references
199 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).